- Home
- HOWL vs ACET Comparison
HOWL vs ACET Comparison
Compare HOWL & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- ACET
- Stock Information
- Founded
- HOWL 2017
- ACET 1947
- Country
- HOWL United States
- ACET United States
- Employees
- HOWL N/A
- ACET N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- ACET Health Care
- Exchange
- HOWL Nasdaq
- ACET Nasdaq
- Market Cap
- HOWL 37.9M
- ACET 44.4M
- IPO Year
- HOWL 2021
- ACET N/A
- Fundamental
- Price
- HOWL $0.87
- ACET $0.48
- Analyst Decision
- HOWL Strong Buy
- ACET Buy
- Analyst Count
- HOWL 3
- ACET 6
- Target Price
- HOWL $9.00
- ACET $6.00
- AVG Volume (30 Days)
- HOWL 232.7K
- ACET 462.5K
- Earning Date
- HOWL 05-08-2025
- ACET 05-06-2025
- Dividend Yield
- HOWL N/A
- ACET N/A
- EPS Growth
- HOWL N/A
- ACET N/A
- EPS
- HOWL N/A
- ACET N/A
- Revenue
- HOWL $1,143,000.00
- ACET N/A
- Revenue This Year
- HOWL N/A
- ACET N/A
- Revenue Next Year
- HOWL $733.33
- ACET N/A
- P/E Ratio
- HOWL N/A
- ACET N/A
- Revenue Growth
- HOWL N/A
- ACET N/A
- 52 Week Low
- HOWL $0.60
- ACET $0.45
- 52 Week High
- HOWL $6.34
- ACET $1.81
- Technical
- Relative Strength Index (RSI)
- HOWL 46.85
- ACET 34.63
- Support Level
- HOWL $0.80
- ACET $0.61
- Resistance Level
- HOWL $0.97
- ACET $0.70
- Average True Range (ATR)
- HOWL 0.07
- ACET 0.05
- MACD
- HOWL 0.02
- ACET -0.00
- Stochastic Oscillator
- HOWL 41.92
- ACET 2.87
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.